Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04762901
Recruitment Status : Withdrawn (Funding was terminated.)
First Posted : February 21, 2021
Last Update Posted : April 26, 2022
Sponsor:
Collaborator:
Tesaro, Inc.
Information provided by (Responsible Party):
Wake Forest University Health Sciences

Brief Summary:
This is an open-label, two-stage, multi-arm Phase 1 study designed to evaluate the safety and preliminary efficacy of combining niraparib with four standard chemotherapy regimens used to treat TNBC.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Niraparib Drug: Doxorubicin Drug: Cyclophosphamide Drug: Paclitaxel Drug: Pegfilgrastim Drug: Carboplatin Phase 1

Detailed Description:
Niraparib is an oral, selective poly ADP ribose polymerase (PARP)-1 and PARP-2 inhibitor. A strategy of combining a PARP inhibitor, as a chemopotentiator, with chemotherapy is a promising approach in the treatment of triple-negative breast cancer. This study will evaluate the combination of niraparib with several standard chemotherapy regimens used to treat breast cancer to determine a recommended Stage 2 dose (RS2D) of chemotherapy regimens with niraparib. Stage 1 will be conducted in subjects with metastatic TNBC and will include 4 chemotherapy treatment arms in escalating dose levels (Arm 1: doxorubicin + cyclophosphamide (AC) every 14 days with pegfilgrastim (or biosimilar) for 4 cycles followed by AC every 21 days; Arm 2: AC every 21 days; Arm 3: weekly paclitaxel; Arm 4: weekly paclitaxel + carboplatin every 21 days), each combined with oral daily niraparib. Treatment will continue until disease progression, unacceptable toxicity, or subject withdrawal.Stage 2 will be conducted in subjects with non-metastatic TNBC. Subjects will receive neoadjuvant chemotherapy with either AC every 14 days (Arm 1A) or every 21 days (Arm 2A) at the RS2D of chemotherapy combined with oral daily niraparib from Stage 1. Treatment will continue for 4 cycles.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: LCI-BRE-MTN-NIR-001: A Phase I Study of Niraparib in Combination With Standard Chemotherapy in Metastatic Triple-Negative Breast Cancer
Estimated Study Start Date : April 1, 2021
Estimated Primary Completion Date : January 2026
Estimated Study Completion Date : January 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Stage 1 Arm 1
Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles, followed by AC IV every 21 days
Drug: Niraparib
Oral tablet
Other Name: ZEJULA

Drug: Doxorubicin
IV

Drug: Cyclophosphamide
IV

Drug: Pegfilgrastim
Injection

Experimental: Stage 1 Arm 2
Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
Drug: Niraparib
Oral tablet
Other Name: ZEJULA

Drug: Doxorubicin
IV

Drug: Cyclophosphamide
IV

Experimental: Stage 1 Arm 3
Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, 15, and 22 every 28 days
Drug: Niraparib
Oral tablet
Other Name: ZEJULA

Drug: Paclitaxel
IV

Experimental: Stage 1 Arm 4
Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, and 15 every 21 days and carboplatin IV every 21 days
Drug: Niraparib
Oral tablet
Other Name: ZEJULA

Drug: Paclitaxel
IV

Drug: Carboplatin
IV

Experimental: Stage 2 Arm 1
Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles
Drug: Niraparib
Oral tablet
Other Name: ZEJULA

Drug: Doxorubicin
IV

Drug: Cyclophosphamide
IV

Drug: Pegfilgrastim
Injection

Experimental: Stage 2 Arm 2
Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
Drug: Niraparib
Oral tablet
Other Name: ZEJULA

Drug: Doxorubicin
IV

Drug: Cyclophosphamide
IV




Primary Outcome Measures :
  1. Stage 1 - Evaluate dose-limiting toxicities (DLT) separately for Arms 1, 2, 3, and 4 and establish recommended Stage 2 dose of chemotherapy in combination with niraparib [ Time Frame: up to 28 days ]
    The DLT variable will be determined for each subject as a binary variability indicating whether or not subject experienced a protocol-defined DLT.

  2. Stage 2 - Assess clinically significant toxicities separately for Arms 1 and 2 after RS2D of niraparib is determined. [ Time Frame: up to 84 days ]
    The clinically significant toxicity variable will be determined for each subject as a binary variable indicating whether or not the subject experienced a niraparib-related dose delay of at least 28 days or a Grade 3 or higher niraparib-related non-hematologic toxicity.


Secondary Outcome Measures :
  1. Stage 1 - Objective response rate (ORR) [ Time Frame: up to 30 days post-treatment discontinuation ]
    Objective response will be determined for each subject in Stage 1 as a binary variable indicating whether or not the subject achieved a best overall response of CR or PR

  2. Stage 1 - Duration of response (DoR) [ Time Frame: up to 5 years post-treatment discontinuation ]
    Duration of Response (DoR) will be determined for subjects in Stage 1 who experience a PR or better and is defined as the duration of time from the first assessment that determined a CR or PR to the date of the first occurrence of progressive disease or death.

  3. Stage 1 - Clinical benefit rate (CBR) [ Time Frame: up to 30 days post-treatment discontinuation ]
    Clinical benefit will be determined for each subject in Stage 1 as a binary variable indicating whether or not the subject achieved a best overall response of CR, PR, or SD

  4. Stage 1 - Progression free survival (PFS) [ Time Frame: up to 5 years post-treatment discontinuation ]
    PFS will be determined for all subjects in Stage 1 and is defined as the duration of time from enrollment to the first occurrence of either progressive disease or death.

  5. Stage 1 - Overall survival (OS) [ Time Frame: up to 5 years post-treatment discontinuation ]
    Overall survival is defined as the duration of time from enrollment to the date of death from any cause.

  6. Stage 1 - Cumulative incidence of secondary malignancies including MDS [ Time Frame: up to 5 years post-treatment discontinuation ]
    Secondary malignancies (including MDS) will be defined as a time to event endpoint and will be calculated from the date of enrollment.

  7. Stage 1 - Overall safety profile - Adverse Events of Special Interest (AESIs) [ Time Frame: up to 30 days post-treatment discontinuation ]
    The AESI variable will be determined for each subject as a binary variability indicating whether or not subject experienced a protocol-defined AESI.

  8. Stage 1 - Overall safety profile - Adverse Events (AEs) [ Time Frame: up to 30 days post-treatment discontinuation ]
    The AE variable will be determined for each subject as a binary variability indicating whether or not subject experienced an AE per CTCAE V5.0.

  9. Stage 1 - Overall safety profile - Death on Study Therapy [ Time Frame: up to 30 days post-treatment discontinuation ]
    The death of study therapy variable will be determined for each subject as a binary variability indicating whether or not subject experienced a Grade 5 event.

  10. Stage 1 - Overall safety profile - Complete Blood Count with Differential (CBCD) [ Time Frame: up to 30 days post-treatment discontinuation ]
    The CBCD variable will be collected quantitatively for each subject.

  11. Stage 1 - Overall safety profile - Comprehensive Metabolic Profile (CMP) [ Time Frame: up to 30 days post-treatment discontinuation ]
    The CMP variable will be collected quantitatively for each subject.

  12. Stage 2 - Pathologic complete response (pCR) [ Time Frame: up to 4 weeks post-surgery ]
    Pathologic complete response (pCR) will be determined for each subject in Stage 2 as a binary variable indicating whether the subject experiences a pCR to neoadjuvant therapy.

  13. Stage 2 - Clinical complete response (cCR) [ Time Frame: up to 4 weeks post-surgery ]
    Clinical complete response (cCR) will be determined for each subject in Stage 2 as a binary variable indicating whether the subject experiences a cCR to neoadjuvant therapy.

  14. Stage 2 - Relapse-free survival [ Time Frame: up to 5 years post-treatment discontinuation ]
    RFS will be determined for all subjects in Stage 2 and is defined as the duration of time from enrollment to the first occurrence of either disease progression prior to surgery, disease relapse after surgery, or death.

  15. Stage 2 - Overall survival [ Time Frame: up to 5 years post-treatment discontinuation ]
    Overall survival is defined as the duration of time from enrollment to the date of death from any cause.

  16. Stage 2 - Cumulative incidence of secondary malignancies including MDS [ Time Frame: up to 5 years post-treatment discontinuation ]
    Secondary malignancies (including MDS) will be defined as a time to event endpoint and will be calculated from the date of enrollment.

  17. Stage 2 - Overall safety profile - Adverse Events of Special Interest (AESIs) [ Time Frame: up to 4 weeks post-surgery ]
    The AESI variable will be determined for each subject as a binary variability indicating whether or not subject experienced a protocol-defined AESI.

  18. Stage 2 - Overall safety profile - Adverse Events (AEs) [ Time Frame: up to 4 weeks post-surgery ]
    The AE variable will be determined for each subject as a binary variability indicating whether or not subject experienced an AE per CTCAE V5.0.

  19. Stage 2 - Overall safety profile - Serious Adverse Events (SAEs) [ Time Frame: up to 4 weeks post-surgery ]
    The SAE variable will be determined for each subject as a binary variability indicating whether or not subject experienced a protocol-defined SAE.

  20. Stage 2 - Overall safety profile - Death on Study Therapy [ Time Frame: up to 4 weeks post-surgery ]
    The death of study therapy variable will be determined for each subject as a binary variability indicating whether or not subject experienced a Grade 5 event.

  21. Stage 2 - Overall safety profile - Complete Blood Count with Differential (CBCD) [ Time Frame: up to 4 weeks post-surgery ]
    The CBCD variable will be collected quantitatively for each subject.

  22. Stage 2 - Overall safety profile - Comprehensive Metabolic Profile (CMP) [ Time Frame: up to 4 weeks post-surgery ]
    The CMP variable will be collected quantitatively for each subject.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Subject must meet all of the following applicable inclusion criteria to participate in this study:

  1. Able to understand and willing to provide written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  2. Male or female and age ≥ 18 years at the time of consent.
  3. ECOG Performance Status of 0, 1 or 2 (Stage 1), or 0-1 (Stage 2) within 14 days prior to day 1 of treatment.
  4. Histologically or cytologically confirmed hormone receptor negative tumor (estrogen and progesterone) on pathology immunohistochemistry (IHC) assessment defined as <10% staining and HER2-negative, non-overexpressing defined by an IHC 0 or 1+ or fluorescence in-situ hybridization (FISH) HER2:CEP17 ratio < 2.0 with an average HER2 gene copy number of <4 signals/nucleus, and:

    Stage 1 (metastatic):

    a. Measurable (by RECIST v1.1) or evaluable lesions

    Stage 2 (non-metastatic, treatment naïve, with no prior excisional biopsy/lumpectomy/LND staging):

    1. Primary tumor size ≥ 2 cm by at least one radiographic or clinical measurement. NOTE: this requirement does not apply to subjects with inflammatory TNBC.
    2. Clinical stage at presentation: cT1c-cT4, cN0-cN3
  5. Tumor tissue:

    Stage 1:

    Willing to provide tumor tissue for research purposes. Fresh biopsy of metastatic lesion prior to day 1 of treatment preferred if feasible. If fresh biopsy of metastatic lesion is not feasible, fresh biopsy can be obtained from the primary tumor site (i.e. breast). Tumor tissue from bone metastases is not acceptable. If fresh biopsy from metastatic tumor or primary tumor site is not possible, archival tumor tissue (formalin-fixed paraffin embedded [FFPE] or tumor block) may be used as long as it is from within 12 months of study entry. NOTE: If tissue is not available within required timeframe (i.e., either fresh or archival) subject will still be eligible for trial.

    Stage 2:

    Willing to undergo fresh biopsy of the primary tumor prior to day 1 of treatment for research purposes (breast is preferred; lymph node is acceptable). If not clinically feasible, then provide archived tumor tissue (FFPE or tumor block) of the primary tumor within 12 months of study entry. If archived tissue will be submitted rather than fresh biopsy, the archived tissue must be assessed and documented by pathology to ensure adequate tumor is present for correlative analysis. NOTE: For subjects who do not have archival tumor tissue available within required timeframe or if archival tissue insufficient, a pre-treatment core biopsy of the primary breast tumor must be obtained. If subjects have inflammatory breast cancer and a core biopsy is not possible, consideration can be given to obtain a skin punch biopsy.

  6. Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 14 days prior to day 1 of treatment.

    • Absolute Neutrophil Count (ANC): greater than or equal to 1,000/µL
    • Platelet Count greater than or equal to 100,000/µL without platelet transfusion within 4 weeks of day 1 of treatment
    • Hemoglobin (Hgb): greater than or equal to 9 g/dL without red blood cell transfusion within 4 weeks of day 1 of treatment
    • Serum creatinine (SCr): less than or equal to 1.5 × upper limit of normal (ULN)
  7. For subjects anticipated to receive anthracyclines, adequate cardiac function as defined by ≥50% Left Ventricular Ejection Fraction (LVEF) by ECHO or MUGA within 28 days prior to day 1 of treatment.
  8. Females of childbearing potential (FCBP) must have a negative serum pregnancy test within 7 days prior to day 1 of treatment and documented. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or are postmenopausal (>45 years of age and at least 12 consecutive months with no menses without an alternative medical cause).
  9. FCBP must be willing to use a highly effective contraceptive method (i.e., highly effective achieves a failure rate of <1% per year when used consistently and correctly) or a combination method from the time of informed consent until 30 days after treatment discontinuation. Contraceptive methods with low user dependency are preferable but not required.

    Acceptable methods of contraception (highly effective) are:

    Single method (one of the following is acceptable):

    • Non-hormonal Intrauterine device (IUD)
    • Vasectomy of a female subject's partner
    • Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.

    Combination method (requires use of two of the following):

    • Diaphragm with spermicide (Cannot be used in conjunction with cervical cap/spermicide)
    • Cervical cap with spermicide (nulliparous women only)
    • Contraceptive sponge with spermicide (nulliparous women only)
    • Male condom or female condom (cannot be used together) with spermicide
  10. Male subjects with female partners who are of child-bearing potential, should use a highly effective method of contraception during niraparib therapy and for 90 days after receiving the last dose of niraparib.
  11. Subjects must agree to not donate blood for 90 days after receiving the last dose of niraparib.
  12. Female subjects must agree to not breastfeed during the study or for 30 days after the last dose of study treatment and male subjects must not donate sperm during niraparib therapy and for 90 days after receiving the last dose of niraparib.
  13. As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study.
  14. Ability to swallow oral medications.

Stage 1 Exclusion Criteria

Subjects meeting any of the criteria below may not participate in Stage 1 of the study:

  1. Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Note: Subjects with previously treated brain metastases may participate if there is no evidence of disease progression for at least 4 weeks after CNS-directed treatment as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period, are asymptomatic, have no requirement for steroids, no requirement for anticonvulsants, and stable CNS radiographic study showing no significant vasogenic edema ≥ 4 weeks since completion of radiation and ≥ 1 week since discontinuation of steroids. Carcinomatous meningitis precludes a subject from study participation regardless of clinical stability.
  2. More than 3 prior lines of chemotherapy for triple-negative metastatic disease.
  3. Not recovered (i.e., ≥ Grade 1) from adverse events due to agents previously administered; NOTE: Subjects with ≤ Grade 2 neuropathy or alopecia of any grade are an exception.
  4. Prior chemotherapy within 3 weeks, prior targeted small molecule therapy or radiation therapy within 2 weeks, or prior anti-cancer monoclonal antibody for direct anti-neoplastic treatment within 3 weeks prior to day 1 of treatment.
  5. History or known allergic reaction to doxorubicin, cyclophosphamide, paclitaxel or carboplatin.
  6. For Arm 1, any prior anthracycline exposure.
  7. For Arm 2, prior doxorubicin exposure of > 300 mg/m2 or equivalent anthracycline exposure (i.e. epirubicin dose > 540 mg/m2).

Stage 2 Exclusion Criteria

Subjects meeting any of the criteria below may not participate in Stage 2 of the study:

  1. Final needle aspirate (FNA) alone to diagnose primary breast cancer.
  2. Excisional biopsy or lumpectomy performed prior to screening.
  3. Surgical axillary staging procedure prior to screening; NOTE: the following procedures are permitted prior to screening:

    1. FNA or core biopsy of an axillary node for any subject
    2. Although not recommended, a pre-neoadjuvant therapy sentinel node (SN) biopsy for subjects with clinically negative axillary nodes
  4. Definitive radiologic evidence of metastatic disease.
  5. History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral ductal carcinoma in-situ (DCIS) treated with radiotherapy (NOTE: subjects with a lobular CIS (LCIS) are eligible).
  6. Treatment including chemotherapy, radiation, and/or targeted therapy administered for the currently diagnosed breast cancer prior to screening.
  7. Previous therapy with anthracyclines for any malignancy.
  8. History of known allergic reaction to doxorubicin or cyclophosphamide.

Overall Exclusion Criteria

Subjects meeting any of the criteria below may not participate in the study:

  1. Active infection requiring systemic therapy (NOTE: at discretion of investigator, subjects with uncomplicated urinary tract infections may be eligible).
  2. Major surgery within 3 weeks of day 1 of treatment.
  3. Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
  4. Has had diagnosis, detection or treatment of another type of cancer ≤ 2 years prior to day 1 of treatment (exceptions include basal cell or squamous cell skin cancer, or in-situ cervical cancer that has been definitively treated).
  5. Known hypersensitivity to the components of niraparib or the excipients.
  6. Prior treatment with any PARP inhibitor.
  7. Has received any other investigational agents within 4 weeks of day 1 of treatment or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to day 1 of treatment.
  8. Has a known history of Human Immunodeficiency Virus (HIV) or known acquired immunodeficiency disorder (AIDS).
  9. Known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
  10. Poor medical risk as evidenced by uncontrolled intercurrent illness including, but not limited to, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator.
  11. Received a transfusion (platelets or red blood cells) ≤ 4 weeks of day 1 of treatment.
  12. Subject has a condition (such as transfusion dependent anemia or thrombocytopenia) that might confound the results of the study or interfere with the subject's participation for the full duration of the study treatment or that makes it not in the best interest of the subject to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04762901


Sponsors and Collaborators
Wake Forest University Health Sciences
Tesaro, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Antoinette Tan, MD Wake Forest University Health Sciences
Layout table for additonal information
Responsible Party: Wake Forest University Health Sciences
ClinicalTrials.gov Identifier: NCT04762901    
Other Study ID Numbers: LCI-BRE-MTN-NIR-001
00048055 ( Other Identifier: Advarra IRB )
First Posted: February 21, 2021    Key Record Dates
Last Update Posted: April 26, 2022
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Wake Forest University Health Sciences:
Triple-negative
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Cyclophosphamide
Carboplatin
Doxorubicin
Niraparib
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors